Literature DB >> 21050182

The cell biology of major histocompatibility complex class I assembly: towards a molecular understanding.

A Van Hateren1, E James, A Bailey, A Phillips, N Dalchau, T Elliott.   

Abstract

Major histocompatibility complex class I (MHC I) proteins protect the host from intracellular pathogens and cellular abnormalities through the binding of peptide fragments derived primarily from intracellular proteins. These peptide-MHC complexes are displayed at the cell surface for inspection by cytotoxic T lymphocytes. Here we reveal how MHC I molecules achieve this feat in the face of numerous levels of quality control. Among these is the chaperone tapasin, which governs peptide selection in the endoplasmic reticulum as part of the peptide-loading complex, and we propose key amino acid interactions central to the peptide selection mechanism. We discuss how the aminopeptidase ERAAP fine-tunes the peptide repertoire available to assembling MHC I molecules, before focusing on the journey of MHC I molecules through the secretory pathway, where calreticulin provides additional regulation of MHC I expression. Lastly we discuss how these processes culminate to influence immune responses.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21050182     DOI: 10.1111/j.1399-0039.2010.01550.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  27 in total

1.  Productive association between MHC class I and tapasin requires the tapasin transmembrane/cytosolic region and the tapasin C-terminal Ig-like domain.

Authors:  Laura C Simone; Corey J Georgesen; Peter D Simone; Xiaojian Wang; Joyce C Solheim
Journal:  Mol Immunol       Date:  2011-12-12       Impact factor: 4.407

Review 2.  Regulation of the Cell Biology of Antigen Cross-Presentation.

Authors:  J Magarian Blander
Journal:  Annu Rev Immunol       Date:  2018-02-28       Impact factor: 28.527

Review 3.  ERAP1 in the pathogenesis of ankylosing spondylitis.

Authors:  Emma Reeves; Tim Elliott; Edward James; Christopher J Edwards
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

4.  A mechanistic basis for the co-evolution of chicken tapasin and major histocompatibility complex class I (MHC I) proteins.

Authors:  Andy van Hateren; Rachel Carter; Alistair Bailey; Nasia Kontouli; Anthony P Williams; Jim Kaufman; Tim Elliott
Journal:  J Biol Chem       Date:  2013-09-27       Impact factor: 5.157

5.  Dipeptides catalyze rapid peptide exchange on MHC class I molecules.

Authors:  Sunil Kumar Saini; Heiko Schuster; Venkat Raman Ramnarayan; Hans-Georg Rammensee; Stefan Stevanović; Sebastian Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

Review 6.  Structural aspects of chaperone-mediated peptide loading in the MHC-I antigen presentation pathway.

Authors:  Kannan Natarajan; Jiansheng Jiang; David H Margulies
Journal:  Crit Rev Biochem Mol Biol       Date:  2019-05-14       Impact factor: 8.250

7.  A role for UDP-glucose glycoprotein glucosyltransferase in expression and quality control of MHC class I molecules.

Authors:  Wei Zhang; Pamela A Wearsch; Yajuan Zhu; Ralf M Leonhardt; Peter Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-07       Impact factor: 11.205

Review 8.  Antigen processing and immune regulation in the response to tumours.

Authors:  Emma Reeves; Edward James
Journal:  Immunology       Date:  2016-10-12       Impact factor: 7.397

9.  Tapasin-related protein TAPBPR is an additional component of the MHC class I presentation pathway.

Authors:  Louise H Boyle; Clemens Hermann; Jessica M Boname; Keith M Porter; Peysh A Patel; Marian L Burr; Lidia M Duncan; Michael E Harbour; David A Rhodes; Karsten Skjødt; Paul J Lehner; John Trowsdale
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

10.  The binding of TAPBPR and Tapasin to MHC class I is mutually exclusive.

Authors:  Clemens Hermann; Lisa M Strittmatter; Janet E Deane; Louise H Boyle
Journal:  J Immunol       Date:  2013-10-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.